3Bennett MI,Rayment C,Hjermstad M,et a1.Caraceni A,Kaasa S.Prevalence and aetiology of neuropathic pain in cancer patients:a systematic review.pain,2012,153(2):359-365.
4Wilson J,Stack C,Hester J.Recent advances in cancer pain management.F1000 Prime Rep,2014,3(6):10.doi:10.12703/P6-10.
5Bhatia G,Lau ME,Koury KM,et a1.Intrathecal Drug Delivery(ITDD)systems for cancer pain.F1000Res,2013,2:96.
6Cahana A,Dansie EJ,Theodore BR,et a1.Redesigning Delivery of Opioids to Optimize Pain Management,Improve Outcomes,and Contain Costs.Pain Med,2013,14:36-42.
7Levy MH.Pharmacologic management of cancer pain.Semin Oncol,1994.2l:7l8-739.
8Bray F,Jemal A,Grey N,et a1.Global cancer transitions according to the Human Development Index(2008-2030):a populat ion-based study.Lancet Oncol,2012,13(8):790-801.
10Gulati A,Puttanniah V,Hung J,Malhotra V.Considerations for evaluating the use of intrathecal drug delivery in the oncologic patient.Curr Pain Headache Rep.2014,18(2):391.doi:10.1007/s11916-013-0391-2.
